Michael Lahn

3.5k citations
42 papers · 2.2k indexed · 1 hit paper · h-index 23

Impact in

  • Oncology top 2%
    • Cancer Cells and Metastasis
    • Pancreatic and Hepatic Oncology Research
    • Cancer Immunotherapy and Biomarkers
    • Cancer, Hypoxia, and Metabolism

Papers in

    • Pancreatic and Hepatic Oncology Research 8
    • Colorectal Cancer Treatments and Studies 6
    • Cancer Treatment and Pharmacology 4
    • Cancer, Hypoxia, and Metabolism 11

Michael Lahn

42 papers receiving 2.2k citations

Hit Papers

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway 2015 · 453 citations
4532015202620182022100200300400

Peers

Michael Lahn
Comparison fields: 5 of 93
  • Oncology 1.1k
  • Cancer Research 400
  • Hepatology 175
  • Molecular Biology 1.3k
  • Genetics 203
Replace Jeff Sosman with:
Jeff Sosman United States
Yoshihiko Kitajima Japan
Bin Shi China
Karim A. Benhadji United States
Dana T. Aftab United States
William Cruz‐Muñoz Canada
Vassiliki Kotoula Greece
Jacques Gaudreault United States
Laura Boldrini Italy
Vincenzo Damiano Italy
Michael Lahn relative to Jeff Sosman United States Jeff Sosman's profile →
Citations per field
00.5×7.1×
Jeff Sosman · 1×
Citations per year

Countries citing papers authored by Michael Lahn

Since Specialization
Citations

This map shows the geographic impact of Michael Lahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lahn more than expected).

Fields of papers citing papers by Michael Lahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lahn. The network helps show where Michael Lahn may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Lahn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Lahn Line = papers co-authored together Michael Lahn links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 202046
2 201539
3 2014200
4 201430
5 201491
6 201481
7 2011195
8 201025
9 201020
10 200922
11 200921
12 200911
13 200813
14 200730
15 200725
16 200717
17 20073
18 200619
19 200432
20 200439

About Michael Lahn

Michael Lahn is a scholar working on Oncology, Cancer Research, Toxicology, Genetics and Molecular Biology, having authored 42 papers that have together received 2.2k indexed citations. Recurring topics across this work include TGF-β signaling in diseases (20 papers), Cancer, Hypoxia, and Metabolism (11 papers), Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Glioma Diagnosis and Treatment (5 papers), Cancer Treatment and Pharmacology (4 papers), Melanoma and MAPK Pathways (4 papers) and Genetic factors in colorectal cancer (3 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (400 citations), Hepatology (175 citations), Molecular Biology (1.3k citations) and Genetics (203 citations). Michael Lahn has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ann Cleverly, Gianluigi Giannelli, Ivelina Gueorguieva, Erica Villa, Karim A. Benhadji, Shawn T. Estrem, Anja J. Stauber, Kyla Driscoll, Stephan Herbertz and Christopher A. Slapak. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Annals of Oncology, Biomarkers and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026